20 articles
A sponsored 90-day trial of enhanced-absorption quercetin targeting cholesterol, blood sugar, and metabolic age was terminated before completion.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
Researchers found a dual-target approach that selectively destroys the most treatment-resistant form of acute myeloid leukemia.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
Daily anthocyanin supplementation helped over half of prediabetic participants return to normal glucose tolerance in just 12 weeks.
Combined mitochondrial therapy restored muscle function and reduced fatigue in mouse model of Gulf War Illness.
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
Experimental diabetes drug IC7Fc reduces cholesterol and artery plaque buildup, offering cardiovascular benefits even without weight loss.
A comprehensive review finds SGLT2 inhibitors reduce AKI risk in humans via hemodynamic, metabolic, and cellular protective pathways.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
SGLT2 inhibitor canagliflozin prevents cardiovascular harm from low-sodium diets in diabetic kidney disease patients.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
Blocking mTOR forces cancer cells to rewire cholesterol uptake and transport, revealing new drug targets when combined with rapamycin.
New research identifies choline kinase alpha as a key driver of diabetic retinopathy and microvascular dysfunction.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
Major trial of 10,251 diabetics reveals surprising outcomes from aggressive blood sugar, blood pressure, and cholesterol management.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
